Writing letters helped curb physicians from overprescribing medicines

Writing letters to physicians who prescribe higher than average amount of a prescription drug has helped cut back, according to new research published in JAMA Psychiatry.

The study looked at prescriptions of the antipsychotic drug Seroquel, which helps people diagnosed with schizophrenia, bipolar disorder and other serious mental illnesses. However, the drug can be deadly—and doctors who prescribed the drug the most were easily convinced to cut back prescriptions as a result of the letters.

Working with researchers in the study, Medicare sent letters to about 5,000 general practitioners who prescribed the drug the most, including peer comparisons that showed how less frequently other doctors prescribed Seroquel.

Over a nine-month period, the peer comparison letter caused “substantial and durable reductions” in prescribing, the study found. Physicians cut back prescriptions nearly 16 percent over an extended period of two years.

The study was overseen by an interdisciplinary team at CMS and the U.S. Office of Evaluation Sciences, as well as review board at Columbia University, Harvard University and the Massachusetts Institute of Technology.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.